Other ASH Meetings

Highlights and interviews from the American Society of Hematology’s meetings.

  • Harnessing the Power of Gene Editing Thursday, September 1st, 2016 | September 2016, Volume 2, Issue 9

    For years, scientists have been manipulating genes in animal and human cells to gain a better understanding of how genomes work, with an eye toward developing improved medical treatments. Gene editing, in particular, involves using nucleases – enzymes that essentially act as “molecular scissors” – to cut DNA strands and insert, delete, or replace a […]

  • Tazemetostat for Patients with Pretreated Non-Hodgkin Lymphoma Monday, August 1st, 2016 | August 2016, Volume 2, Issue 8

    Preliminary data from an ongoing, global, phase II trial of tazemetostat, a first-in-class EZH2 inhibitor, in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) showed “encouraging” safety and efficacy, according to lead author Franck Morschhauser, MD, PhD, who presented the findings at the 2016 ASH Meeting on Lymphoma Biology. “These patients, especially those with highly […]

  • R-EPOCH May Be Viable Option for Patients with High-Risk DLBCL Monday, August 1st, 2016 | August 2016, Volume 2, Issue 8

    Results from a single-center study show that the drug combination R-EPOCH leads to a high overall response rate (ORR) in patients with high-risk diffuse large B-cell lymphoma (DLBCL). Researchers also found that rates of complete response (CR) were higher among patients who received dose-adjusted R-EPOCH. Up to 40 percent of patients with DLBCL who receive […]

  • Ibrutinib Shows Survival Benefit in Previously Treated CLL/SLL Patients with High-Risk Disease Monday, August 1st, 2016 | August 2016, Volume 2, Issue 8

    Longer-term data from the phase III RESONATE trial – a head-to-head comparison of ibrutinib and ofatumumab – continue to demonstrate ibrutinib’s efficacy in patients with previously treated chronic lymphocytic leukemia (CLL), according to data presented at the 2016 ASH Meeting on Lymphoma Biology. The benefits also appear to extend to patients with high-risk genetic mutations […]

  • ASH Sickle Cell Disease Summit: A Call to Action Tuesday, May 19th, 2015 | May 2015, Volume 1, Issue 5

    In mid-April, more than 60 experts in sickle cell disease (SCD), including clinicians and researchers, federal agency partners, representatives from industry, and other members of the SCD community convened at ASH Headquarters in Washington, DC, for the ASH Sickle Cell Disease Summit: A Call to Action, with the goal of advancing outcomes for individuals with […]

1 of 2
back to top